Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PKY.AX
SellPathkey.AI Ltd · Healthcare · Australia · $57M · Avg Vol: $145K/d
21
StockRankGet insider-trade alerts
Q
20
V
20
M
63
P/E (TTM)
—
ROE
-1344.9%
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0.9M | 0.6M | 0.4M | — | -32.8% | 0.3M |
| EPS (AUD) | -0.00 | -0.00 | -0.00 | -0.00 | — | -0.01 |
| Shares | 1.2B | 1.2B | 1.2B | 1.2B | 0.0% | 1.4B |
| Debt | — | 0.3M | — | — | — | — |
| Equity | 0.3M | -0.4M | -90.2K | — | — | — |
| Op CF | -1.5M | -1.4M | -2.1M | — | — | -1.1M |
| Inv CF | -10.4K | -2.2K | -17.7K | — | — | — |
| Fin CF | — | 1.0M | 2.0M | — | — | — |
Loading 1Y...
PRICE (1Y)+21.6%
SMA 50SMA 200
Close
$0.0322
RSI (14)
70.6
52W High
$0.0537
From 52W High
0.6%
SCORE BREAKDOWN
Quality
20
ROIC (ROA)
-137.9%*4.7
ROE
-1344.9%0.5
GP/Assets
—N/A
Op. Margin
-6396.6%3.2
FCF/Assets
—N/A
Piotroski
440.0
Int. Cover
—N/A
D/E Ratio
—N/A
Current Ratio
2.44x47.1
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-8.7x25.0
P/FCF
—N/A
P/B
19.5x5.9
P/S
181.4x5.4
Div Yield
—N/A
Momentum
63
52W High %
60%35.3
RS 6M
68%93.6
SMA 50/200
1.38x96.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$57M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PKY.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PKY.AX | Pathkey.AI Ltd(you) | $57M | 21 | Sell |
| PHX.AX | PharmX Technologies Limited | $59M | 22 | Sell |
| BB1.AX | BlinkLab Limited | $86M | 21 | Sell |
| ALC.AX | Alcidion Group Limited | $93M | 54 | Hold |
| EIQ.AX | Echo IQ Limited | $740M | 28 | Sell |
| AYA.AX | Artrya Limited | $557M | 35 | Hold |
| PTX.AX | Prescient Therapeutics Limited | $50M | 22 | Sell |
| LTP.AX | LTR Pharma Limited | $61M | 24 | Sell |
| SOM.AX | SomnoMed Limited | $53M | 27 | Sell |
| ALA.AX | Arovella Therapeutics Limited | $53M | 14 | Strong Sell |
Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 61.9%